Clinical trial
A Study of Tasisulam in Treating Participants With Malignant Melanoma
NCT00383292 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00383292 |
|---|---|
| Title | A Study of Tasisulam in Treating Participants With Malignant Melanoma |
| Official title | A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | tasisulam |
| Enrollment | 130 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Jul 1, 2015 |
| First posted | Oct 3, 2006 |
| Last update posted | Jun 6, 2018 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: